Sfoglia per AUTORE
BERGAMO F
Collezione ASL Biella

  

Items : 9

Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study. in Targeted oncology / Target Oncol. 2024 May;19(3):359-370. doi: 10.1007/s11523-024-01060-1. Epub 2024 May 1.

2024
ASL Biella
AOU Città della Salute di Torino

Stefano C; Rimassa L; Casadei-Gardini A; Antonuzzo L; Vivaldi C; Rizzato MD; Foti S; De Braud F; De Rosa A; Ratti F; Aldrighetti L; Fornaro L; Niger M; Zanuso V; Garattini SK; Satolli MA; Rossari F; Brandi G; Brunetti O; Leone F; Pirrone C; Diana A; Toma I; Pretta A; Lorenzo A; Landriscina M; Gusmaroli E; Bergamo F; Balsano R; et alii...

Modified FOLFOXIRI plus cetuximab and avelumab as initial therapy in RAS wild-type unresectable metastatic colorectal cancer: Results of the phase II AVETRIC trial by GONO in Annals of Oncology

2023
ASL Biella

Conca V; Antoniotti C; Bergamo F; Pietrantonio F; Rossini D; Scartozzi M; Perissinotto E; Leone A; Pusceddu V; Borelli B; Cavanna L; Latiano T; Santini D; Masi G; Salvatore L; Frassineti G; Leone F; Tamberi S; Boni L; Cremolini C;

Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial. in ESMO open / ESMO Open. 2020 Sep;5(5):e000911. doi: 10.1136/esmoopen-2020-000911.

2020
ASL Biella

Siena S; Marsoni S; Trusolino L; Bardelli A; Sapino A; Vanzulli A; Regge D; Cappello G; Bonoldi E; Torri V; Bencardino K; Valtorta E; Ardizzoni A; Grassi E; Amatu A; Ciardiello F; Zagonel V; Bergamo F; Martino C; Fenocchio E; Tosi F; Leone F; Ghezzi S; Lonardi S; Sartore-Bianchi A;

Author Correction: Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant Chemotherapy. in Scientific reports / Sci Rep. 2020 Jan 31;10(1):1918. doi: 10.1038/s41598-020-58486-6.

2020
ASL Biella

Magnani M; Frontini L; Sobrero A; Bergamo F; Lazzarelli S; Verusio C; Turci D; Biondi E; Bramati A; Foltran L; Nicolini M; Ricci V; Barni S; Veltri E; Sozzi P; Ionta MT; Bagaloni I; Zagonel V; Pella N; Mucciarini C; Massidda B; Labianca R; Lonardi S; Ronzoni M; Graziano F; Galli F; Galli F; Ruzzo A; Rulli E; et alii...

Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer. in Clinical colorectal cancer / Clin Colorectal Cancer. 2020 Dec;19(4):256-262.e2. doi: 10.1016/j.clcc.2020.06.009. Epub 2020 Jun 27

2020
ASL Biella

Leone F; Ghezzi S; Martino C; Bencardino K; Bonazzina E; Bergamo F; Fenocchio E; Martinelli E; Troiani T; Siravegna G; Mauri G; Marsoni S; Siena S; Trusolino L; Bardelli A; Zagonel V; Regge D; Ciardiello F; Bonoldi E; Vanzulli A; Marrapese G; Valtorta E; Tosi F; Cappello G; Cassingena A; Torri V; Amatu A; Lonardi S; Sartore-Bianchi A; et alii...

Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant Chemotherapy. in Scientific reports / Sci Rep. 2019 Aug 8;9(1):11527. doi: 10.1038/s41598-019-47627-1.

2019
ASL Biella

Magnani M; Frontini L; Sobrero A; Bergamo F; Lazzarelli S; Verusio C; Turci D; Biondi E; Bramati A; Foltran L; Nicolini M; Ricci V; Barni S; Veltri E; Sozzi P; Ionta MT; Bagaloni I; Zagonel V; Pella N; Mucciarini C; Massidda B; Labianca R; Lonardi S; Ronzoni M; Graziano F; Galli F; Galli F; Ruzzo A; Rulli E; et alii...

Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients. in British journal of cancer / Br J Cancer. 2017 Oct 24;117(9):1269-1277. doi: 10.1038/bjc.2017.289. Epub 2017 Aug 24.

2017
ASL Biella

Magnani M; Frontini L; Sobrero A; Verusio C; Bergamo F; Bramati A; Lazzarelli S; Turci D; Biondi E; Foltran L; Nicolini M; Ricci V; Barni S; Bagaloni I; Veltri E; Sozzi P; Ionta MT; Labianca R; Zagonel V; Pella N; Mucciarini C; Rulli E; Galli F; Massidda B; Ronzoni M; Lonardi S; Ruzzo A; Galli F; Graziano F; et alii...

Genetic markers for toxicity of adjuvant oxaliplatin and fluoropyrimidines in the phase III TOSCA trial in high-risk colon cancer patients. in Scientific reports / Sci Rep. 2014 Nov 5;4:6828. doi: 10.1038/srep06828.

2014
ASL Biella

Magnani M; Verusio C; Frontini L; Sobrero A; Bergamo F; Turci D; Lazzarelli S; Bramati A; Foltran L; Biondi E; Nicolini M; Mucciarini C; Labianca R; Ionta MT; Veltri E; Sozzi P; Barni S; Ricci V; Pella N; Lonardi S; Ronzoni M; Massidda B; Zagonel V; Galli F; Floriani I; Rulli E; Graziano F; Galli F; Giacomini E; et alii...

Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer in Annals of Oncology

2014
ASL Biella
AO Cuneo
AOU Città della Salute di Torino
ASL Cuneo 2

Bajetta E; Floriani I; Di Bartolomeo M; Labianca R; Falcone A; Di Costanzo F; Comella G; Amadori D; Pinto C; Carlomagno C; Nitti D; Daniele B; Mini E; Poli D; Santoro A; Mosconi S; Casaretti R; Boni C; Pinotti G; Bidoli P; Landi L; Rosati G; Ravaioli A; Cantore M; Di Fabio F; Aitini E; Marchet A; Rulli E; Cropalato Di Tullio M; et alii...